Olema Pharmaceuticals, Inc. (OLMA) Dividend History

Company News

• Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

  Olema Oncology announced the selection of a 90 mg once-daily dose of palazestrant for its Phase 3 OPERA-01 monotherapy trial and OPERA-02 combination trial with ribociclib. The company will present a trial-in-progress poster for OPERA-01 at the ASCO 2025 Annual Meeting.

  GlobeNewswire Inc.
• Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight

  The metastatic HR+/HER2- breast cancer market is expected to grow due to the launch of several novel emerging therapies, which are anticipated to change the treatment landscape and improve survival outcomes for this patient population.

  GlobeNewswire Inc.

  Featured Companies: ARVN LLY PFE
• Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

  Olema Oncology presented preclinical data demonstrating the anti-tumor activity of OP-3136, a KAT6 inhibitor, in prostate, ovarian, and non-small cell lung cancer models. The data showed potent tumor growth inhibition and sustained tumor regression in various cancer models, supporting the potential utility of OP-3136 beyond breast cancer.

  GlobeNewswire Inc.
• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has granted stock options to three new employees to purchase a total of 26,200 shares of the company's common stock. The stock options have a 10-year term and an exercise price of $5.57 per share.

  GlobeNewswire Inc.
• Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

  Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its President and CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is focused on developing targeted therapies for breast cancer, with its lead product candidate, palazestrant, currently in a Phase 3 clinical trial.

  GlobeNewswire Inc.